Effect of 8 Weeks of Resistance Training With Blood Flow Restriction on Muscle Strength, Clinical Parameters, Biochemical Biomarkers, and Perceived Exertion in Adults With Obesity

Condition(s) studied

Investigational drug(s) / intervention(s)

Intervention: The BFR group will perform machine-based quadriceps extension exercises and dumbbell biceps curls involving both lower limbs and both upper limbs. Each exercise will consist of 4 sets of 12 repetitions. Quadriceps extensions will be performed at an intensity of 40% of one-repetition maximum (1RM), and biceps curls at 20% of 1RM. The execution cadence will be standardized to 1 second for the concentric phase and 2 seconds for the eccentric phase. Inter-set rest intervals will be 1 minute. For vascular occlusion, a Carbafix cuff (8 cm width × 68 cm length for the upper limb; 10.5 cm width × 106.0 cm length for the lower limb) will be applied directly to the skin at the most proximal portion of the arm or thigh. The cuff will be inflated to 20 mmHg above resting brachial systolic blood pressure. To ensure partial vascular occlusion, pulse and oxygen saturation will be assessed using a pulse oximeter at the end of each set. Cuff pressure will be released during the inter-set rest periods.

Intervention: The control group will perform quadriceps extensions and biceps curls, completing 4 sets of 10 repetitions at an intensity of 70% of one-repetition maximum (1RM). The execution tempo will be standardized to 1 second for the concentric phase and 2 seconds for the eccentric phase, with 2-minute inter-set rest intervals. The protocol will adhere to the resistance training guidelines established by the American College of Sports Medicine (ACSM)

Study summary

To analyze the effect of 8 weeks of resistance training with blood flow restriction on muscle strength, clinical parameters, biochemical biomarkers, and perceived exertion in adults with obesity.

Eligibility

Primary outcome measure(s)

• Muscle strength — Baseline and after 8 weeks
  Muscle strength (kg): Change from baseline to 8 weeks of intervention. Muscle strength will be assessed using dynamometry
• Dynamic muscle strength — Baseline and after 8 weeks
  Dynamic muscle strength (kg): Change from baseline to 8 weeks of intervention.
• Arm circumference — Baseline and after 8 weeks
  Arm circumference (cm): Change from baseline to 8 weeks of intervention. Measurements will be obtained using a non-elastic measuring tape in accordance with the International Society for the Advancement of Kinanthropometry (ISAK) protocol
• Thigh circumference — Baseline and after 8 weeks
  Thigh circumference (cm): Change from baseline to 8 weeks of intervention. Measurements will be obtained using a non-elastic measuring tape in accordance with the International Society for the Advancement of Kinanthropometry (ISAK) protocol
• Maximum oxygen uptake (VO₂max) — Baseline and after 8 weeks
  VO₂max (ml/min/kg): Change from Baseline at 8 weeks, measured using a submaximal exercise test based on the Åstrand-Ryhming protocol
• Systolic blood pressure (SBP) — Baseline and after 8 weeks
  SBP (mmHg): Changes from baseline to 8 weeks of intervention
• Diastolic blood pressure (DBP) — Baseline and after 8 weeks
  DBP (mmHg): Changes from baseline to 8 weeks of intervention
• Heart rate — Baseline and after 8 weeks
  Heart rate (bpm): Change from baseline to 8 weeks of intervention.
• Glucose — Baseline and after 8 weeks
  Glucose (mg/dl): Changes from baseline to 8 weeks of intervention
• Triglycerides — Baseline and after 8 weeks
  Triglycerides (mg/dl): Changes from baseline to 8 weeks of intervention
• Total cholesterol — Baseline and after 8 weeks
  Total cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
• HDL cholesterol — Baseline and after 8 weeks
  HDL cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
• LDL cholesterol — Baseline and after 8 weeks
  LDL cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
• C-reactive protein (CRP) — Baseline and after 8 weeks
  CRP (mg/dl): Changes from baseline to 8 weeks of intervention
• Interleukin-6 (IL-6) — Baseline and after 8 weeks
  IL-6 (pg/mL):Change from baseline to 8 weeks of intervention.
• Tumor Necrosis Factor Alpha (TNF-α) — Baseline and after 8 weeks
  TNF-α (pg/mL): Change from baseline to 8 weeks of intervention
• Weight — Baseline and after 8 weeks
  Weight (kg): Changes in weight from baseline to 8 weeks of intervention.
• Height — Baseline and after 8 weeks
  Height (cm): Changes in height from baseline to 8 weeks of intervention
• Body mass index (BMI) — Baseline and after 8 weeks
  BMI (kg/m\^2): Change from Baseline at 8 weeks, calculated by: weight (kg)/ height (m\^2).
• Body fat percentage — Baseline and after 8 weeks
  Body fat percentage (%): Changes in body fat assessed by bioelectrical impedance analysis (BIA)
• Muscle mass percentage — Baseline and after 8 weeks
  Muscle mass percentage (%): Changes in muscle mass measured using bioelectrical impedance analysis (BIA)
• Perceived Exertion — Baseline and after 8 weeks
  Perceived exertion will be assessed using the Rating of Perceived Exertion Scale (RPE)
• Exercise enjoyment — Baseline and after 8 weeks
  Exercise enjoyment will be assessed using the validated Physical Activity Enjoyment Scale Questionnaire (PACES)

Trial sites (1)

More Centro Universitario de Tlajomulco, Universidad de Guadalajara trials in Mexico

Other trials for the same condition